Prostate Cancer

The decision to watch and wait was right for my dad and for our family, and being able to talk about all the options with the doctor and primary nurse helped us make the right decision.

Retiree Greg Kelly has a passion and affinity for model building.

Faced with a late-in-life diagnosis of prostate cancer, Bill Sneddon describes his positive experience with Proton therapy, the emerging alternative treatment to standard x-ray radiation.

You know Ben Stiller as the comedic actor who made you laugh in “There’s Something About Mary,” “Zoolander,” and “Meet the Parents,” but this legend of the silver screen credits a PSA screening for saving his life.

Here is some valuable advice regarding being a care partner. Kristin Ainsworth learns that taking care of her husband, who was diagnosed with prostate cancer, also requires her taking care of herself.

On February 14, 2018, the FDA approved Erleada (apalutamide; from Janssen) for the treatment of patients with nonmetastatic, castration-resistant prostate cancer.

A doctor’s mistake left Richard Churchill reeling, but during treatment for prostate cancer he found solace in nature and in many new relationships with patients, caregivers, and family members.

Frank dela Rama explains the options available today, the limitations, and possibilities in the future for the diagnosis of prostate cancer.

Oncology navigator Frank dela Rama lists the screening tools available now for diagnosing prostate cancer.

Frank dela Rama talks about some of the stigma and miscommunication surrounding prostate cancer screening and the need for clarity.

Frank dela Rama explains the current recommendations for screening for prostate cancer.

Retiree Greg Kelly has a passion and affinity for model building.

Dennis Golden was an active, fit, 70-year-old when he learned he had prostate cancer. He was surprised to discover that few men know the warning signs and how potentially serious it can be. In response, he formed the National Prostate Cancer Awareness Foundation to educate men about this disease.

Results of a new study showed that the combination of Cabometyx (cabozantinib) and the immune checkpoint inhibitor Tecentriq (atezolizumab) was safe and effective in men with metastatic (spreading) castration-resistant prostate cancer, the most common type of prostate cancer.

The PARP inhibitor Lynparza (olaparib), a type of drug that is usually used for the treatment of women with ovarian cancer, has also been studied in men with prostate cancer. The results of the PROfound clinical trial were recently presented at the 2020 ASCO annual meeting by Antoine Thiery-Vuillemin, MD, PhD, Centre Hospitalier de Besançon, France.

In December 2020, the FDA approved Orgovyx (relugolix), as the first oral hormone therapy for the treatment of men with advanced prostate cancer. This new drug may eliminate the need to visit the clinic for treatment, helping patients with cancer avoid unnecessary exposure during the pandemic.

Dr. Matthew Allaway is a testicular cancer survivor and a practicing urologist. He describes a new procedure he created to ease the difficulty of diagnosing prostate cancer, the most common cancer among men in the United States.

This article presents recent studies that shed light on racial disparities in the treatment of black and white men who are diagnosed with prostate cancer.

Dr. Daniel Vorobiof provides an overview of prostate cancer, including prevention tips and risk factors, diagnosis, treatment options, and specific questions to consider asking your doctor.

A decade after his son passed away from a rare form of bone cancer at age 16, Mark DeLong was diagnosed with prostate cancer. He learned, among other things, the healing power of being vulnerable and sharing personal stories.

Denis Finnegan, EdD, a retired U.S. Navy officer, recalls his fear of being diagnosed with and undergoing treatment for prostate cancer, and mustering the courage to tell his wife. This experience changed his world.

When should you start and stop screening for prostate cancer? The answer can be complicated, because each man needs to balance individually the benefits and harms of a screening test.

Prostate cancer is the second most common cancer in American men; roughly 1 in 8 men will be diagnosed with it. Dr. Brooks offers important, practical information, including screening, for men about this all-too-common disease.

Find financial assistance programs available for prostate cancer drugs.